Purchase this article with an account.
Jarka Plskova, Kathrin Greiner, Elizabeth Muckersie, Linda Duncan, John V. Forrester; Interferon-α: A Key Factor in Autoimmune Disease?. Invest. Ophthalmol. Vis. Sci. 2006;47(9):3946-3950. https://doi.org/10.1167/iovs.06-0058.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. Interferon (IFN)-α is an effective drug for treatment of uveitis in Behçet’s disease. This study was undertaken to investigate the mechanism of action of IFN-α in the treatment of various types of noninfectious sight-threatening uveitis.
methods. Eleven patients with refractory uveitis, and 13 healthy individuals were enrolled. The number of circulating plasmacytoid dendritic cells (pDCs) and their capacity to produce IFN-α in culture on stimulation with synthetic oligodinucleotides containing the CpG-motif were studied. Peripheral blood CD4+ T-cell phenotype and activation status were evaluated by flow cytometry at 0, 2, and 8 weeks after treatment for expression of CD69, CD62L, chemokine receptors (CCR4, CXCR3, and CCR5), and intracellular cytokines (TNF-α, IFN-γ, and IL-10).
results. All patients experienced a positive clinical response to IFN-α treatment. There was no significant difference between patients and control subjects in the number of circulating pDCs, but there was a significant decrease in the capability of patients’ pDCs to produce IFN-α in response to CpG (P < 0.001). Peripheral blood CD4+ T cells expressed reduced levels of surface CD62L (P < 0.005) as a measure of activation and higher levels of chemokine receptors CXCR3, CCR4, and CCR5 (P < 0.005, P < 0.05, and P < 0.05, respectively); in addition, intracellular T-cell IL-10 levels were increased once the treatment was initiated (P < 0.01).
conclusions. The data suggest that IFN-α may control uveitis by promoting induction of IL-10-producing T-cells, possibly T-regulatory cells. Dysregulation of the T-cell population in patients with uveitis may be associated with a defect in the pDCs’ ability to produce IFN-α, which can be circumvented with administration of exogenous IFN-α.
This PDF is available to Subscribers Only